1. Scrip
  3. >>Earnings

Bristol’s Growth Plan Faces First Test In 2022

New Drugs Hit $1bn Mark In 2021, But First Revlimid Generics Launch This Year

 
• By Mandy Jackson

Zeposia, Reblozyl, Breyanzi and Abecma turned BMS’s new product portfolio into a blockbuster revenue stream last year to help fill the $3.5bn gap created by Revlimid and Abraxane generics.

Set of Three Increasing Size Red and White Cartoon Spaceships on Dark Background
BMS will launch three new products, pending approvals, in the US in 2022 • Source: Alamy

Bristol Myers Squibb Company spent the past year laying out its plan for growth through the end of this decade as its three top-selling products lose exclusivity. While 2022 will be the first year that the company’s strategy is put to the test as Revlimid (lenalidomide) faces its first generic competition, the contribution of new product launches to Bristol’s revenue in 2021 suggests that plan is off to a good start.

BMS reported on 4 February that its full-year 2021 product sales totaled $46.4bn, up 9% from 2020, including $12bn in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.

Stock Watch: Generics Firms Trapped Between US Tariffs And European Austerity

 
• By Andy Smith

Successive annual reductions in European drug prices following the pandemic are affecting the global sales of generic pharmaceutical companies. Additionally, the imposition of US import tariffs may result in generic drug supply becoming unprofitable.

Stock Watch: On Q1 Vaccine Sales And Measles Outbreaks

 
• By Andy Smith

A recent study suggested that measles could become endemic in the US due to low vaccination rates. However, first-quarter vaccine sales offered a more nuanced picture.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

More from Business